Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.57 |
| ▸ | MME | P08473 | 9/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877184 | 0.88 | LDHA (0.68) | LDHAPPARGMDM2 | |
| SCHEMBL27801722 | 0.85 | MME (0.54) | LDHAMMEPPARGPPARA | |
| SCHEMBL1768283 | 0.83 | KDM6B (0.56) | LDHAMMEPPARGPPARAFPR2 | |
| SCHEMBL1867578 | 0.83 | ACACB (0.49) | LDHAMMEPPARGPPARA | |
| SCHEMBL1768284 | 0.83 | KDM6B (0.56) | LDHAMMEPPARGPPARAFPR2 | |
| SCHEMBL18921686 | 0.83 | MME (0.45) | LDHAMMEPPARGPPARA | |
| SCHEMBL27807869 | 0.83 | MME (0.51) | LDHAMMEPPARGPPARAFPR2 | |
| SCHEMBL18248079 | 0.83 | KDM6B (0.56) | LDHAMMEPPARGPPARAFPR2 | |
| SCHEMBL44832 | 0.81 | SLC7A5 (0.69) | — | |
| SCHEMBL3007531 | 0.81 | MME (0.68) | MMEPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0367131-B1 | Light-sensitive composition | BASF AG (DE) | 1995-02-22 | — | — | EP | claimed |
| US-5035979-A | Radiation-sensitive mixture | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-30 | — | — | US | claimed |
| US-12168655-B2 | Apelin receptor agonists and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-17 | — | — | US | disclosed |
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| US-11390616-B2 | Apelin receptor agonists and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-19 | — | — | US | disclosed |
| CN-108473466-B | Apelin receptor agonists and methods of use | 百时美施贵宝公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3383860-B1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3383860-B1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10336717-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336717-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-1059300-A1 | Indenyl compounds for the polymerisation of olefins | DSM N.V. (NL) | 2000-12-13 | — | — | EP | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| WO-2000017211-A1 | PHOSPHONIC ACIDS DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA & CO. (CA) | 2000-03-30 | — | — | WO | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0771795-A1 | New glycomimetics as Selectin antagonists, and anti-imflammation pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| US-5035979-A | Radiation-sensitive mixture | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-30 | — | — | US | disclosed |
| US-4329495-A | USEFUL AS ANALGESICS OR ANTICONVULSANTS, CHIRAL 2-(2-BENZYL-3-MERCAPTOPROPIONYLAMINO)-THIOBUTYRIC ACIDS, OR ALKANOL DERIVATIVES | PFIZER INC. (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390616-B2 | Apelin receptor agonists and methods of use | APLNR, AP2B1, AP3B1 | LDHA 4735/4885MME 559/4885PPARG 260/4885 |
| US-10336717-B2 | Inhibitors of beta-secretase | BACE1, BACE2, PSEN1 | LDHA 4091/4885MME 15/4885PPARG 4235/4885 |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | LDHA 4735/4885MME 559/4885PPARG 260/4885 |
| US-12168655-B2 | Apelin receptor agonists and methods of use | APLNR, AP2B1, AP3B1 | LDHA 4735/4885MME 559/4885PPARG 260/4885 |
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | LDHA 4735/4885MME 559/4885PPARG 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.